Twist Bioscience Corporation · NASDAQ:TWST
Twist Bioscience — Q4 2025 Earnings Presentation
20 slides from Twist Bioscience's earnings presentation, Nov 14, 2025
Slide 1: Fiscal 2025 4Q and Full Year Financial Results
Fiscal 2025 4Q and Full Year Financial Results NOVE MB ER 2025
Slide 2: Agenda
Agenda Welcome Angela Bitting SVP, Corporate Affairs Quarterly Highlights Emily Leproust Chief Executive Officer Business Highlights Patrick Finn President and Chief Operating Officer Financial and Operational Performance Adam Laponis Chief Financial Officer Milestones Emily Leproust Chief Executive
Slide 3: Legal Disclaimers
Legal Disclaimers This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private S
Slide 4: Financial Results
Financial Results
Slide 5: Highlights from the Quarter
Highlights from the Quarter $(7.8)M Adj $99.0M Revenue 51.3% Gross Margin EBITDA* Beat guidance Guidance of Guidance of of ~$96-98M 51% to 52% $(6.0)M to $(8.0)M *Adjusted EBITDA is defined as net in come (loss) adjuste d to exclu de inte rest income, income tax expense, de preciation and amortiza t
Slide 6: Highlights from the Year
Highlights from the Year $(46.9)M Adj $376.6M Revenue 50.7% Gross Margin EBITDA* Guidance of Guidance of Guidance of ~$374-376M 50.5% to 51.0% $(45.0)M to $(47.0)M Cash, Cash Equivalents and Short-term Investments as of 9/30/25 as *See adjusted EBITDA reconciliation on page 19. $232.4 million 6 | TW
Slide 7: SynBio: 4Q FY25, FY25, Next Up
1 SynBio Write 4Q FY25 FY25 NEXT UP • $39.5 million in revenue • $145.0 million in revenue ✓ Adapter off fragments • Ultra complex genes • Growth of 17% YoY • Growth of 17% YoY ✓ Expanded vectors • Longer genes • Shipped approximately ✓ IgG characterization 938,000 genes • mRNA ✓ Enzyme engineering
Slide 8: NGS: 4Q FY25, FY25, Next Up
2 NGS Read 4Q FY25 FY25 NEXT UP • $53.0 million in revenue • $208.1 million in ✓ FlexPrep library prep • MRD Express revenue ✓ Element Trinity Freestyle • Oncology CGP RNA • Growth of 16% YoY • Growth of 23% YoY on-flowcell enrichment • Launched Trinity Freestyle • DNA extraction kit Fast Hybridizat
Slide 9: Biopharma Solutions: 4Q FY25, FY25, Next Up
3 Biopharma Solutions 4Q FY25 FY25 NEXT UP • $6.4 million in revenue • $23.5 million in revenue ✓ Yeast display for • Increased scale optimization • Growth of 22% YoY • Growth of 15% YoY • Custom library generation ✓ Humanized mice for • $11.5 million in orders • $30 million in orders • Libraries wi
Slide 10: Combined Biopharma Business
3 Biopharma Solutions Combined Biopharma Business 84 47 Active Programs Programs Started Broad Disease Indications Cancer, Neurology, 442 Immuno-oncology, Partners Infectious Disease, Canine / Feline, Other 1,182 82 Varied Completed Milestones/ Modalities Programs Royalties mAbs, Bispecific Antibodi
Slide 11: Crossing the Threshold to Profitability
Crossing the Threshold to Profitability Continued revenue and margin growth Strong operational and commercial execution Platform enhancements and new products Adjusted EBITDA Breakeven Market and wallet share expansion Growing markets 11 | TWIST BIOSCIENCE | PROPRIETARY
Slide 12: Strong Quarterly Revenue Growth
Strong Quarterly Revenue Growth $ in Millions Biopharma $99.0 $96.1 NGS $92.8 $88.7 SynBio $84.7 $81.5 $75.3 $71.5 $66.9 $63.7 $60.2 $56.1 $57.3 $54.2 $48.1 $42.0 $38.0 $35.0 $32.4 $31.2 $28.2 $21.2 $19.3 $15.7 $17.2 $13.6 $13.6 $11.5 Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep D
Slide 13: Revenue by Geography
Revenue by Geography $ in Millions Americas EMEA APAC Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep FY2018 0 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 13 | TWIST BIOSCIENCE | PROPRIETARY
Slide 14: Adjusted EBITDA Progress Toward Break-even
Adjusted EBITDA Progress Toward Break-even $ Millions $96.1 $99.0 $92.8 $88.7 $81.5 $84.7 $75.3 $71.5 53.4% 51.3% $63.7 $66.9 GM 49.6% GM GM 48.3% 45.1% GM 43.3% GM 41.0% GM 40.5% GM GM 36.6% 34.4% GM GM FY23Q3 FY23Q4 FY24Q1 FY24Q2 FY24Q3 FY24Q4 FY25Q1 FY25Q2 FY25Q3 FY25Q4 Adj. SG&A + Adj. R&D* $58.
Slide 15: FY2026 Guidance
From quarterly update - to discuss with AB FY2026 Guidance Q1 FY2026 Q4 FY2026 FY2026 Guidance * Guidance * Guidance * $425 to $435M*** $100 to $101M DNA Synthesis and Protein Solutions: Revenue Approximately equivalent for DNA Synthesis and $194 to $199M Protein Solutions as well as NGS Application
Slide 16: Our Next Chapter
Our Next Chapter Continued revenue and margin growth Strong operational and commercial execution Platform enhancements and new products Market and wallet share expansion Growing markets Market Understanding Culture of Innovation Proven Technology Strong Differentiation Scalable Infrastructure Commer
Slide 17: Writing the Future
Writing the Future
Slide 18: Additional Slides
Additional Slides
Slide 19: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation (In Thousands) Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2024 FY2025 GAAP Net Income (loss) $(46,243) $(43,008) $(45,492) (85,571) $(34,655) $(31,594) $(39,328) $20,390 $(27,138) $(208,726) $(77,670) Add (Deduct) Adjustments: Interest I
Slide 20: Adjusted R&D and SG&A Expenses Reconciliation
Adjusted R&D and SG&A Expenses Reconciliation (In Millions) Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2024 FY 2025 R&D Expenses — GAAP $23.7 $23.1 $24.1 $22.5 $21.1 $21.3 $23.9 $18.0 $17.0 $90.9 $80.3 Adjusted to exclude: Depreciation and 0.8 0.9 0.9 0.9 0.5 0.4 0.4